"Vasoconstrictor Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause constriction of the blood vessels.
| Descriptor ID |
D014662
|
| MeSH Number(s) |
D27.505.954.411.793
|
| Concept/Terms |
Vasoconstrictor Agents- Vasoconstrictor Agents
- Agents, Vasoconstrictor
- Vasoconstrictor Drugs
- Drugs, Vasoconstrictor
- Vasoconstrictors
- Vasoactive Agonists
- Agonists, Vasoactive
- Vasopressor Agents
- Agents, Vasopressor
|
Below are MeSH descriptors whose meaning is more general than "Vasoconstrictor Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasoconstrictor Agents".
This graph shows the total number of publications written about "Vasoconstrictor Agents" by people in this website by year, and whether "Vasoconstrictor Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 3 | 1 | 4 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 6 | 10 |
| 2021 | 1 | 4 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 0 | 2 |
| 2025 | 4 | 2 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasoconstrictor Agents" by people in Profiles.
-
Management Strategies for Patients With Multiple Extremity Necrosis Following Life-Sustaining Vasosupportive Intensive Care. J Hand Surg Am. 2026 03; 51(3):334-347.
-
Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome. Clin Gastroenterol Hepatol. 2026 Apr; 24(4):1079-1091.
-
Comparative Effectiveness of Less vs. More Frequent Hydrocortisone Dosing in Septic Shock. Crit Care Explor. 2025 Sep 01; 7(9):e1316.
-
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1192-1201.
-
Impaired contractile response of human peripheral arterioles to angiotensin II after cardiopulmonary bypass. Surgery. 2025 Oct; 186:109518.
-
Intraosseous vs Intravenous Access for Epinephrine in Pediatric Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2025 06 02; 8(6):e2517291.
-
The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy. Crit Care Explor. 2024 Oct; 6(10):e1156.
-
Comparing risk of post infection erectile dysfunction following SARS Coronavirus 2 stratified by acute and long COVID, hospitalization status, and vasopressor administration: a U.S. large claims database analysis. Int J Impot Res. 2025 May; 37(5):366-371.
-
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology. 2024 05 01; 79(5):1048-1064.
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. 2024 04 01; 30(4):347-355.